Business Description
Satellos Bioscience Inc
NAICS : 541710
SIC : 3741
ISIN : CA80401L3083
Total Employee Number:
21Description
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 12.2 | |||||
3-Year EPS without NRI Growth Rate | 8.6 | |||||
3-Year FCF Growth Rate | -4.6 | |||||
3-Year Book Growth Rate | 36.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -5.33 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.1 | |||||
9-Day RSI | 71.24 | |||||
14-Day RSI | 69.14 | |||||
3-1 Month Momentum % | -20.04 | |||||
6-1 Month Momentum % | -24.05 | |||||
12-1 Month Momentum % | 15.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.49 | |||||
Quick Ratio | 16.49 | |||||
Cash Ratio | 15.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -64.3 | |||||
Shareholder Yield % | -24.22 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -66.53 | |||||
ROA % | -61.44 | |||||
ROIC % | -10274.51 | |||||
3-Year ROIIC % | 725.73 | |||||
ROC (Joel Greenblatt) % | -79390.38 | |||||
ROCE % | -70.08 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.76 | |||||
Price-to-Tangible-Book | 2.76 | |||||
EV-to-EBIT | -4.08 | |||||
EV-to-EBITDA | -4.08 | |||||
EV-to-FCF | -4.74 | |||||
| Price-to-Net-Current-Asset-Value | 2.76 | |||||
| Price-to-Net-Cash | 2.99 | |||||
Earnings Yield (Greenblatt) % | -24.51 | |||||
FCF Yield % | -13.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Satellos Bioscience Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -2.407 | ||
| Beta | 1.232 | ||
| 3-Year Sharpe Ratio | 0.59 | ||
| 3-Year Sortino Ratio | 1.27 | ||
| Volatility % | 121.55 | ||
| 14-Day RSI | 69.14 | ||
| 14-Day ATR (C$) | 0.899432 | ||
| 20-Day SMA (C$) | 10.1175 | ||
| 12-1 Month Momentum % | 15.23 | ||
| 52-Week Range (C$) | 6.36 - 18.98 | ||
| Shares Outstanding (Mil) | 20.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Satellos Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Satellos Bioscience Inc Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| 0.0833333:1 Stock Split | 2026-01-30 | 15.12 (+1.61%) |
Show
Entries
Satellos Bioscience Inc Frequently Asked Questions
What is Satellos Bioscience Inc(TSX:MSCL)'s stock price today?
The current price of TSX:MSCL is C$12.85. The 52 week high of TSX:MSCL is C$18.98 and 52 week low is C$6.36.
When is next earnings date of Satellos Bioscience Inc(TSX:MSCL)?
The next earnings date of Satellos Bioscience Inc(TSX:MSCL) is .
Does Satellos Bioscience Inc(TSX:MSCL) pay dividends? If so, how much?
Satellos Bioscience Inc(TSX:MSCL) does not pay dividend.
Press Release
Articles on Satellos Bioscience Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers